I-Ju Liu
Overview
Explore the profile of I-Ju Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1107
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yeh N, Lin T, Liu I, Hu S, Hsu T, Chin H, et al.
Int J Biol Macromol
. 2024 Sep;
279(Pt 3):135271.
PMID: 39233170
Due to the heterogeneity of the tumor microenvironment, the clinical efficacy of tumor treatment is not satisfied, highlighting the necessity for new strategies to tackle this issue. To effectively treat...
2.
Liang K, Chih H, Liu I, Yeh N, Hsu T, Chin H, et al.
J Colloid Interface Sci
. 2024 Aug;
677(Pt A):400-415.
PMID: 39096708
Chemodynamic therapy (CDT), an emerging cancer treatment modality, uses multivalent metal elements to convert endogenous hydrogen peroxide (HO) to toxic hydroxyl radicals (•OH) via a Fenton or Fenton-like reaction, thus...
3.
Chen Y, Liu I, Lin T, Tsai M, Hu S, Hsu T, et al.
Int J Biol Macromol
. 2024 Apr;
266(Pt 2):131359.
PMID: 38580018
The combination of photothermal therapy (PTT) and photodynamic therapy (PDT) has emerged as a promising strategy for cancer treatment. However, the poor photostability and photothermal conversion efficiency (PCE) of organic...
4.
Li P, Liao M, Cheng P, Liang J, Liu I, Chiu C, et al.
PLoS Negl Trop Dis
. 2024 Mar;
18(3):e0012031.
PMID: 38478493
[This corrects the article DOI: 10.1371/journal.pntd.0001636.].
5.
Lee W, Chen X, Liu I, Lee J, Hu C, Wu H, et al.
Cell Rep
. 2022 Oct;
41(4):111555.
PMID: 36288706
Upregulation of interleukin-17 receptor B (IL-17RB) is known to be oncogenic, while other IL-17 receptors and ligands are generally involved in pro-inflammatory pathways. We identify a mouse neutralizing monoclonal antibody...
6.
Liou L, Wang T, Liu I, Wu H, Ke P, Fang Y, et al.
Lupus
. 2022 May;
31(8):927-938.
PMID: 35531921
Objective: To study the association of α2,6-sialic acid (SIA) content in serum IgG anti-dsDNA with human systemic lupus erythematosus disease activity index (SLEDAI) and the effect of sialylated and desialylated...
7.
Huang H, Sung Y, Li C, Wan D, Chao P, Tseng Y, et al.
Gut
. 2021 Dec;
71(9):1843-1855.
PMID: 34921062
Objective: Stromal barriers, such as the abundant desmoplastic stroma that is characteristic of pancreatic ductal adenocarcinoma (PDAC), can block the delivery and decrease the tumour-penetrating ability of therapeutics such as...
8.
Su S, Yang T, Yu P, Liang K, Chen W, Yang C, et al.
PLoS Pathog
. 2021 Oct;
17(10):e1009704.
PMID: 34673836
Development of effective therapeutics for mitigating the COVID-19 pandemic is a pressing global need. Neutralizing antibodies are known to be effective antivirals, as they can be rapidly deployed to prevent...
9.
Wang Y, Liu I, Chen K, Wu H
Oncogenesis
. 2021 Sep;
10(8):59.
PMID: 34465724
Epidermal growth factor receptor (EGFR) remains the sole druggable molecular target other than the PD1/PD-L1 pathway with meaningful clinical benefit in squamous cell carcinoma of head and neck (SCCHN). Human...
10.
Guo J, Liu I, Lin H, Wang M, Chang Y, Lin S, et al.
J Biomed Sci
. 2021 Jun;
28(1):43.
PMID: 34098950
Background: Coronavirus disease 19 (COVID-19) first appeared in the city of Wuhan, in the Hubei province of China. Since its emergence, the COVID-19-causing virus, SARS-CoV-2, has been rapidly transmitted around...